Hoffmann-La Roche

Why trials sponsored by Hoffmann-La Roche stopped, in this sample of ClinicalTrials.gov.

28 stopped trials with a clear reason; 75% ended for non-scientific reasons.

Trials

• A COPD Data Registry for Participants With Frequent Exacerbations
  NCT07059273 · WITHDRAWN · funding business
  “The study was withdrawn due to a business decision.”
• The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan
  NCT03912350 · WITHDRAWN · funding business
  “The study is on hold due to stopping of the Autism Spectrum Disorder program with balovatpan, the study drug.”
• An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
  NCT05315713 · TERMINATED · funding business
  “Study was terminated due to Sponsor decision.”
• A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
  NCT05256134 · TERMINATED · futility
  “Decision to terminate development of gantenerumab for treatment of people at risk for or at earliest stages of Alzheimer disease (AD) following results of a pre-planned analysis of safety \& efficacy of gantenerumab in Graduate I\&II (WN29922/WN39658).”
• A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
  NCT05129280 · TERMINATED · funding business
  “The study was terminated due to program discontinuation.”
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
  NCT04222972 · TERMINATED · funding business
  “Early termination of the study resulted from organizational and commercial decisions that led to the discontinuation of pralsetinib's global marketing and development in all territories (excluding US and Greater China).”
• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
  NCT04236141 · TERMINATED · funding business
  “Sponsor's decision, no safety concerns”
• A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
  NCT04404140 · TERMINATED · safety
  “Despite many risk-minimization strategies, the combination of ipatasertib, atezolizumab and docetaxel was challenging due to multiple study treatment modifications required to manage toxicity, making further enrollment inappropriate.”
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
  NCT04029688 · TERMINATED · funding business
  “Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed beyond Part 1b.”
• A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
  NCT03669640 · TERMINATED · futility
  “This study was discontinued due to an interim analysis which indicated that ralmitaront was unlikely to meet its primary endpoint.”
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
  NCT03555149 · TERMINATED · slow accrual
  “The Sponsor made the decision to terminate the study due to start up and recruitment issues caused by limited resource availability at the treating centers.”
• An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
  NCT03491150 · TERMINATED · futility
  “This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.”
• A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
  NCT03369964 · WITHDRAWN · funding business
  “Business decision: no safety or efficacy concerns.”
• A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke
  NCT02928393 · TERMINATED · slow accrual
  “Low participant enrolment”
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
  NCT02670083 · TERMINATED · futility
  “This study was discontinued due to an interim analysis in this study, which indicated that Crenezumab was unlikely to meet its primary endpoint.”
• Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD
  NCT02515669 · TERMINATED · futility
  “A pre-planned futility analysis indicated lack of efficacy in study NCT03039686 and led to discontinuation of both ongoing studies in DMD.”
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
  NCT02118584 · TERMINATED · funding business
  “The study was terminated due to program discontinuation, based on mixed efficacy results in the parent studies. There were no safety concerns.”
• A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
  NCT01875003 · TERMINATED · funding business
  “Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.”
• An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis
  NCT01575769 · TERMINATED · funding business
  “The study was terminated prior to the planned final on-treatment efficacy assessments due to commercial availability of tocilizumab in Russia and Poland.”
• A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
  NCT01156961 · WITHDRAWN · logistics pi
  “Absence of patient's recruitment in the study due to administrative reasons”
• A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs
  NCT01209702 · TERMINATED · futility
  “Recruitment halted: Failed to achieve efficacy”
• A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
  NCT00576901 · TERMINATED · slow accrual
  “The sample for statistical analysis of results could not be recruited within the specified timeframe upon retirement of the original principal investigator.”
• A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.
  NCT00454246 · TERMINATED · funding business
  “Strategic decision unrelated to safety or efficacy”
• A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.
  NCT00442416 · TERMINATED · funding business
  “Strategic decision unrelated to safety or efficacy”
• A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B
  NCT02608060 · TERMINATED · slow accrual
  “Due to poor enrollment this study was terminated prematurely.”
• Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
  NCT02739594 · TERMINATED · slow accrual
  “Slow recruitment”
• A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)
  NCT00422942 · TERMINATED · slow accrual
  “Study was terminated after enrollment of 3 participants due to recruitment difficulties.”
• A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer
  NCT02013765 · TERMINATED · slow accrual
  “Trial was terminated prematurely because of recruitment difficulties.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.